Ajanta Pharma Limited (NSE: AJANTPHARM) and Piramal Pharma Ltd (NSE: PPLPHARMA) are both listed in the Pharmaceuticals industry. Ajanta Pharma has a market capitalisation of ₹42,432 Cr and Piramal Pharma ₹31,892 Cr, as of 9 Nov 2026. Return on equity is 25.39% for Ajanta Pharma and -4.00% for Piramal Pharma. Over one year, Ajanta Pharma's share price is up 35.7% and Piramal Pharma's is up 21.7%.
| Metric | Ajanta Pharma | Piramal Pharma |
|---|---|---|
| NSE Symbol | AJANTPHARM | PPLPHARMA |
| BSE Code | 532331 | 543635 |
| Share Price | ₹3,345.50 | ₹245.30 |
| Market Cap | ₹42,432 Cr | ₹31,892 Cr |
| P/E Ratio | 40.2 | Not meaningful (loss) |
| Return on Equity | 25.39% | -4.00% |
| Return on Assets | 14.85% | 0.36% |
| Dividend Yield | 1.88% | 0.00% |
| Beta (1Y) | 0.12 | 0.31 |
| 1-Year Price Change | +35.7% | +21.7% |
| 3-Month Price Change | -4.6% | +14.8% |
| 52-Week Range | ₹2,445.80 – ₹3,796.00 | ₹132.30 – ₹250.40 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹1,794 Cr | ₹2,617 Cr |
| Quarterly Net Profit | ₹388 Cr | ₹5 Cr |
| Net Margin | 21.6% | 0.2% |
| EPS (Basic, Quarter) | ₹31.07 | ₹0.04 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 19…
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generi…
Ajanta Pharma has a market capitalisation of ₹42,432 Cr, against ₹31,892 Cr for Piramal Pharma as of 9 Nov 2026, about 1.3 times the size by market cap.
Ajanta Pharma has a return on equity of 25.39% and Piramal Pharma -4.00%.
Ajanta Pharma's share price is up 35.7% over one year and Piramal Pharma's is up 21.7%.
Ajanta Pharma reported revenue of ₹1,794 Cr and net profit of ₹388 Cr for Q2 FY27. Piramal Pharma reported revenue of ₹2,617 Cr and net profit of ₹5 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.